[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexual-dysfunction-female\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexual-dysfunction-female":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,93,114,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100621860","effects-of-infertility-and-assisted-reproductive-technology-on-sexual-function-and-behavior-100621860",false,"NCT07376109","Effects of Infertility and Assisted Reproductive Technology on Sexual Function and Behavior","Effect of Infertility and Assisted Reproductive Technology (ART) on Sexual Function and Behaviour","Inclusion Criteria:\n\n1. Assigned female at birth.\n2. Self-identify as a woman.\n3. Age 18-44 years.\n4. Diagnosis of infertility.\n5. Seeking fertility treatment at the MUHC Reproductive Centre.\n\nExclusion Criteria:\n\n1. Assigned male at birth.\n2. Age 45 years or older.\n3. Sexual practices that do not allow for the possibility of conception (e.g., same-sex relationships without use of assisted reproductive technologies).\n4. Seeking oocyte cryopreservation.\n5. Individuals who do not wish to complete the anonymous questionnaire.","FEMALE","18 Years","44 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This cross-sectional observational study examines how infertility and the use of assisted reproductive technology (ART) are related to sexual function and sexual behaviors in women seeking fertility treatment. Infertility and the stress of ART may be associated with changes in sexual desire, satisfaction, and activity. The purpose is to better understand these associations to support the sexual health and overall well-being of women undergoing fertility care.\n\nWomen who are assigned female at birth, under 45 years old, diagnosed with infertility, and attending appointments at the MUHC Reproductive Centre are invited to take part. Participants will be asked to complete an anonymous questionnaire while waiting for their clinical visit. The questionnaire includes the validated Female Sexual Function Index (FSFI), which measures different aspects of sexual function, and additional questions about sexual activities, such as frequency of intercourse and other behaviors before and after fertility treatments.\n\nParticipants will not provide any identifying information. Completed questionnaires will be placed in a secure collection box to protect confidentiality.\n\nData from approximately 500 participants will be analyzed to explore how infertility type (primary vs. secondary), duration of infertility, and the number of unsuccessful ART cycles relate to sexual function and behavior. Findings from this study may help healthcare providers better recognize and address the sexual health concerns of women with infertility.\n\nThis study is approved by the McGill University Health Centre Research Ethics Board (REB #2025-11459).",[25,26,27,28,29,30,31],"Infertility Assisted Reproductive Technology","Sexual Behavior","Sexual Function","Sexual Dysfunction and Infertility","Sexual Dysfunction Female","Infertility","Assisted Reproductive Techniques",[33,34,35,36,37,38,39,40,41,42],"infertility","Assisted Reproductive Technology","ART","IVF","female sexual function","female sexual function index","FSFI","sexual behavior","sexual dysfunction","women's sexual health","RECRUITING","2026-02-19",{"date":46,"type":47},"2026-02-20","ACTUAL",{"date":49,"type":47},"2026-02-06",{"date":51,"type":21},"2027-01",{"name":53,"class":54},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":78,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":55},"100625756","comparison-of-outpatient-rehabilitation-versus-self-training-for-the-treatment-and-prevention-of-postpartum-pelvic-floor-dysfunction-100625756","NCT07426770","Comparison of Outpatient Rehabilitation Versus Self-training for the Treatment and Prevention of Postpartum Pelvic Floor Dysfunction","Prevention of Female Pelvic Floor Dysfunction Rehabilitation Postpartum.","DDDPREV","Inclusion Criteria:\n\n* 18 years or older\n* This pregnancy was singleton\n* No contraindications for physical activity\n* No connective tissue disorders (for example Ehlers-Danlos syndrome)\n* No neurological disorders to influence pelvic floor symptoms (for example clinically significant spinal disc herniation)\n\nExclusion Criteria:\n\n* Younger than 18 years\n* Twins or triplet pregnancy\n* Contraindications for physical activity\n* Connective tissue disorders\n* Neurological disorders",true,"50 Years",{"count":67,"type":21},80,"INTERVENTIONAL",[70],"NA","The main goal of this study to compare self-training postpartum and training with a specialist support (physiotherapist and physical medicine and rehabilitation doctor) effect on pelvic floor dysfunction prevention and treatment in postpartum period.\n\nHypothesis: The implementation of postpartum rehabilitation helps to alleviate existing symptoms of pelvic floor dysfunction and prevents pelvic floor dysfunction.\n\nStudy goals:\n\n* To objectively evaluate changes in pelvic organ position and pelvic floor muscle function in postpartum period, before and after specialised rehabilitation program\n* To objectively evaluate pelvic floor symptoms and their influence on woman life quality\n* To compare data (changes in pelvic floor muscle coordination and strength, pelvic organ position and changes in life quality according to validated questionnaires)\n\nStudy participants will:\n\n* Get an examination by obstetrician-gynaecologist, physical medicine and rehabilitation doctor and physiotherapist in 6 to 10 weeks postpartum period.\n* One group of participants will attend physiotherapy, biofeedback and electro stimulation procedures with a guidance of a specialist.\n* Other group of participants gets a recommendations and instructions of training and self-trains at home. To remind of training and help record training time \"squeezy\" app (an application designed for a mobile device) will be offered.\n* All groups of participants will be asked to fill life quality related questionnaires: (ICIQ-UI SF: International Consultation on Incontinence Questionnaire; P-QoL: Prolapse Quality-of-Life Questionnaire; PISQ-IR: Pelvic Organ Prolapse\u002F Urinary Incontinence Sexual Questionnaire IUGA revised; FSFI: female sexual function index; MOS-SF36 Medical Outcomes Study Short Form-36).",[73,74,75,76,77,29],"Pelvic Floor Dysfunction","Postpartum Care","Postpartum Comfort","Female Urinary Incontinence and Pelvic Organ Prolapse","Rectus Diastasis",[79,80,81,82,83],"Pelvic floor dysfunction postpartum","Postpartum urinary incontinence","Postpartum sexual dysfunction","Diastasis postpartum","Rehabilitation postpartum","2026-02-16",{"date":86,"type":47},"2026-02-23",{"date":88,"type":47},"2024-01-30",{"date":90,"type":21},"2029-09-30",{"name":92,"class":54},"Vilnius University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":68,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":55},"100568155","vibrator-use-to-improve-sexual-and-pelvic-floor-function-among-urogynecology-patients-100568155","NCT06677541","Vibrator Use to Improve Sexual and Pelvic Floor Function Among Urogynecology Patients","Inclusion Criteria:\n\n* • Women aged 18 and over presenting to the urogynecology clinic.\n\n  * Women diagnosed with one of the following urogynecologic conditions\n\n    o Pelvic organ prolapse, urgency incontinence, overactive bladder, stress urinary incontinence, fecal incontinence, recovering from a urogynecologic surgery over 6 weeks following surgery and clear for intercourse. Patients post op who continue to have pelvic floor dysfunction can be candidates for the study if they continue to have one of the pelvic floor dysfunctions listed.\n  * Patient will be screened with the FSFI and will be eligible if they score less than 26.55\n  * Patient's must be willing to use a vibrator.\n  * Able to provide informed consent.\n  * Not currently using a vibrator or has not used a vibrator in the past 3 months.\n  * Able to read and write in English\n\nExclusion Criteria:\n\n* • Patients with cognitive impairment.\n\n  * Patients with refusal or discomfort with vibrator use.\n  * Currently using a vibrator or has used a vibrator in the past 3 months.\n  * Patients unable to provide informed consent.\n  * Patients not clear for intercourse following their surgery\n  * Patients with surgery within 2 months of recruitment.",{"count":100,"type":21},84,[70],"Limited data exist describing the use and role of vibrators in a urogynecology population and no randomized controlled trials investigating the use of vibrators as a therapeutic tool to enhance sexual and pelvic floor function in urogynecology patients has been conducted. This study aims to evaluate the efficacy of vibrator use in improving sexual and pelvic floor function in urogynecology patients who report sexual dysfunction.",[73,29,104],"Vibrator","2025-01-14",{"date":107,"type":47},"2025-01-15",{"date":109,"type":47},"2024-11-01",{"date":111,"type":21},"2026-01-31",{"name":113,"class":54},"Albany Medical College",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":68,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100571520","therapeutic-education-of-sexual-dysfunctions-in-women-survivors-of-sexual-violence-and-female-genital-mutilation-100571520","NCT06721325","THERAPEUTIC EDUCATION of SEXUAL DYSFUNCTIONS in WOMEN SURVIVORS of SEXUAL VIOLENCE and FEMALE GENITAL MUTILATION","EFFECTIVENESS of THERAPEUTIC EDUCATION in the PREVENTION and MANAGEMENT of SEXUAL DYSFUNCTIONS in WOMEN SURVIVORS of SEXUAL VIOLENCE and FEMALE GENITAL MUTILATION: RANDOMIZED CLINICAL TRIAL","TESDSV","Inclusion Criteria:\n\nWomen who have suffered sexual assault:\n\n* Aged 18 and older\n* No severe psychiatric disorders or any other condition that prevents them from answering questions and questionnaires\n* Emotionally prepared to address the affected physical and sexual sphere\n\nWomen who have undergone Female Genital Mutilation:\n\n* Aged 18 and older\n* No severe psychiatric disorders or inability to answer questions and questionnaires\n* Emotionally prepared to address the affected physical and sexual sphere\n\nExclusion Criteria:\n\n* Women who have suffered sexual assaults in the context of trafficking of women and girls for sexual exploitation.\n* Women who have difficulty understanding the Spanish language.\n* Women who are not psychologically prepared to address their sexuality.","65 Years",{"count":124,"type":21},163,[70],"Violence against women is a problem that affects women all over the planet, causing physical, emotional, and other repercussions for its survivors. Pelvic floor dysfunctions, especially female sexual dysfunctions, are among the most common physical consequences for women who have suffered sexual violence or female genital mutilation. Pelvic floor physiotherapy is the first-line treatment for these dysfunctions, with therapeutic education being one of its main strategies due to its importance in the cognitive approach and for promoting patient adherence to the proposed treatments. Women who are survivors of sexual violence and female genital mutilation, being at risk for these disorders, express the need to receive information about these dysfunctions and their possible treatments. However, it has been shown that their knowledge in this regard is limited. Therefore, a project is proposed with the objective of determining the effectiveness of an intervention based on therapeutic education in the prevention and management of sexual dysfunctions secondary to sexual violence or female genital mutilation. A group educational program is proposed, which allows survivor women to address these dysfunctions in a non-invasive way. Six sessions are planned to promote the development of various competencies: communicating their needs, integrating knowledge about their health problem, identifying and analyzing, decision-making and know-how, problem-solving, using healthcare resources and asserting their rights. This will provide these women a safe space to share their experiences, learn to manage them, acquire knowledge about the pelvic floor, related dysfunctions and their treatment, as well as self-efficacy tools for dealing with sexual dysfunctions.",[128,29,129],"Sexual Abuse of Adult (If Focus of Attention is on Victim)","Female Genital Mutilation",[131,132,133,134],"sexual violence","female genital mutilation","therapeutic education","physiotherapy","NOT_YET_RECRUITING","2024-12-05",{"date":138,"type":47},"2024-12-06",{"date":140,"type":21},"2024-11-30",{"date":142,"type":21},"2026-12-31",{"name":144,"class":54},"University of Alcala",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":122,"enrollmentInfo":153,"targetDuration":4,"studyType":68,"phases":155,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":55},"100464589","phase-2-adipose-tissue-derived-mesenchymal-stem-cell-ad-msc-therapy-for-the-treatment-of-sexual-function-impairment-in-female-100464589","NCT05329662","Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female","Evaluation of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Efficacy for the Treatment of Sexual Function Impairment in Female","Inclusion Criteria:\n\n* Women who are 40 - 50 years of age or older and have not gone through menopause according to Stages of Reproductive Aging Workshop (STRAW) 2011\n* The last menstrual period before participating in the study at least 2 months or more\n* FSH, Estrogen above the menopause:\n* \\+ FSH \\> 40 mIU\u002FmL\n* \\+ Estradiol \\\u003C 30 pg\u002FmL\n* (tested between the 2nd and the 4th day of the menstrual cycle)\n* FSFI \\\u003C 26.55 ± signs of decline in sexual or reproductive functions such as symptoms of premenopausal such as hot flashes, excessive sweating, headaches\n* Normal liver function\n* Normal kidney function\n* Normal cardiovascular function\n* No active bacterial, fungal and viral (HIV, HBV, HCV, syphilis) infections\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Previous surgery to remove gonads\n* No sexual activity\n* Diagnosed with cancer and is being or has not been treated\n* Had an organ transplant\n* Has congenital malformations related to the gonads\n* Chronic disease such as: Diabetes, hypopituitarism, adrenal insufficiency, blood pressure unresponsive to treatment, etc\n* Any active autoimmune diseases\n* Being diagnosed with heart failure, kidney failure, liver failure, respiratory failure, history of cerebral infarction, myocardial infarction, Alzheimer's\n* Hypothyroidism or hyperthyroidism\n* Any active autoimmune diseases\n* Any clinically significant blood coagulation disorders.\n* History of allergic reaction to anesthetic agents and antibiotics\n* Using hormone therapy within the last 2 weeks or want to use these drugs during the study period\n* Planning to become pregnant during the study period\n* using hormonal contraceptives\n* Absence of menstruation for at least 12 months\n* Mental illness, inability to communicate, inability to answer the interview questions correctly","40 Years",{"count":154,"type":21},130,[156],"PHASE2","Hormones are a chemical substance synthesized and secreted by endocrine gland. Several vital hormones, including Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and Estradiol (E2), play crucial roles in regulating female sexual function.- Hormone therapy is used to treat female hormone deficiency and results in a significant improvement, but long-term use increases cardiovascular disease or cancer risk. Other treatments do not give apparent results. Therefore, it is necessary to develop new and effective treatments to achieve the requirements of improving health in general and sexual health in particularly in women. AD-MSCs have been widely used as autologous and allogeneic stem cell sources to treat numerous disease recently, and they have been proven to be safe. The phase I trial showed that administration of autologous AD-MSCs at the dose of 1.0 x 10\\^6 cells\u002Fkg patient bodyweight was safe for patients with sex hormone deficiency. The therapy introduced potential improvement in sexual and general quality of life indicating by the increased FSFI. Therefore, this phase II trial to evaluate efficiency of autologous adipose tissue-derived mesenchymal stem cells therapy in treatment of female patients with sexual function impairment.",[29],[160,161,162],"sexual dysfunction Female","adipose mesenchymal stem cell","reproductive hormones","2024-06-03",{"date":165,"type":47},"2024-06-04",{"date":167,"type":47},"2023-05-01",{"date":169,"type":21},"2025-12-30",{"name":171,"class":54},"Vinmec Research Institute of Stem Cell and Gene Technology"]